Novartis Cough-Drug Study Is Good News for Glaxo, Barclays Says

Vectura Group Plc and Novartis AG’s positive results in a late-stage study for the experimental QVA149 treatment for smoker’s cough validates a competing drug in development from GlaxoSmithKline Plc, Barclays Capital Inc. analysts said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.